

---

## EU HTA 101 (Update from October 2024)



---

Dr. Thomas Ecker (Editor)

## EU HTA 101

How to prepare for European  
Health Technology Assessment  
for Pharmaceuticals

Update from October 2024

Editor:

Dr. Thomas Ecker

Ecker + Ecker GmbH / Accessus Health GmbH

Hamburg, Germany

Contact: [t.ecker@ecker-ecker.de](mailto:t.ecker@ecker-ecker.de) / [t.ecker@accessus-health.eu](mailto:t.ecker@accessus-health.eu)

ISBN Softcover: 978-3-384-03093-1

ISBN E-Book: 978-3-384-03094-8

© All rights reserved. No part of this book may be reproduced in any form or by any means, especially photocopying, editing, translating, microfilming, and saving to electronic systems, without the prior permission of the publisher, except for uses permitted by copyright law.

The reproduction of generally descriptive terms, trademarks, corporate data, etc, in this book does not imply that these are free for use by anyone. Without separate note, any authorized use is subject to the regulations of trademark law. The rights of the respective trademark owner are to be observed.

The publisher, the authors, and the editor assume that all data and information is complete and correct at the time of the publication. Neither the publisher nor the authors or the editor take any responsibility, explicitly or implicitly, for the content of the book or any potential errors or statements made.

Market Access Core Model® is a registered trademark of Ecker + Ecker GmbH

Project management: Dr. Marie Groneberg, Petra Schulze

Copy editing: Matthew Gaskins (Edition October 2023)

Cover design: sehstrand - Silke Schumacher

Printing and distribution: tredition GmbH, Heinz-Beusen-Stieg 5, 22926 Ahrensburg,  
Germany

---

## Preface

European Health Technology Assessment (EU HTA) is still evolving. In fact, it has not even begun. So why already an update?

The answer is simple: Products that will undergo assessment from 2025 onwards are already in clinical phase 3. Their study design was set long ago. This means that many companies do not have the luxury of “waiting and seeing” until the dust settles. They have to make crucial decisions now to prepare as best they can for a scenario that could not have been anticipated earlier. This urgency to prepare applies not only to them but also to many others who will soon face similar decisions. Both are the audience of this book.

And a lot has happened since the publication of the first edition in October 2023, not least four Implementing Acts and six guidance documents, and one scientific specification.

Most of you might be familiar with preparing national HTA submissions. But EU HTA is different. And it also impacts national submissions. So take the time and reflect upon this new challenge.

The structure of this book follows our Market Access Core Model<sup>®</sup>. At the time of finalizing this book we are at version 2.7 and will continue to evolve, in parallel to adoption of the EU HTA process.

Three words of caution: This book was completed in October 2024, and any changes thereafter have not been taken into account. However, we aim to provide a timely update.

Additionally, it is important to note that the focus of this book is on medicinal products, specifically pharmaceuticals, rather than devices and diagnostics.

Finally, this book provides insights towards an ideal EU HTA process. As such, it bears great promises. But reality not always lives up to this ideal. And especially during the first years of implementation scope of surprise will be rich. So be careful by setting realistic expectations.

Special thanks to all members of our European Partner Network, covering all 27 EU member states, all EEA countries, as well as Switzerland and UK. You provided excellent feedback on the applicability of the Market Access Core Model<sup>®</sup> to your country, and great input towards our internal PICO exercises.

This update would not have been possible without the incredible support of our EU HTA expert group and the contributions of many authors within Ecker + Ecker and Accessus Health.

Thank you very much – you are a fantastic team!



---

## List of contents

<b>Preface .....</b>	<b>V</b>
<b>List of tables .....</b>	<b>XI</b>
<b>List of figures.....</b>	<b>XIII</b>
<b>1 Market Access Core Model .....</b>	<b>1</b>
<b>2 Framework and relevant actors.....</b>	<b>9</b>
2.1 Journey towards the EU HTA regulation: First initiatives and key milestones .....	9
2.1.1 EUnetHTA Project 2006–2008.....	9
2.1.2 EUnetHTA Collaboration 2009.....	12
2.1.3 Joint Actions and beyond .....	12
2.2 Constitutive framework .....	24
2.2.1 Regulation (EU) 2021/2282 (HTAR).....	24
2.2.2 Implementing Acts .....	32
2.2.3 Regulatory approval vs. HTA.....	38
2.2.4 EU pharma legislation .....	40
2.2.5 Guidelines.....	41
2.2.6 Guidance documents by the Coordination Group.....	42
2.2.7 National rules.....	45
2.3 Institutions and stakeholders.....	49
2.3.1 EUnetHTA and EUnetHTA 21 consortium.....	49
2.3.2 Coordination Group on Health Technology Assessment.....	52
2.3.3 European Commission.....	56
2.3.4 Member states.....	57
2.3.5 Stakeholder network.....	57
2.3.6 European Medicines Agency .....	59
<b>3 National Strategy Development .....</b>	<b>61</b>
3.1 Objective and overview .....	61
3.2 WP1.1: Identifying the route of reimbursement .....	63
3.3 WP1.2: PICO simulation .....	65
3.4 WP1.3: Gap analysis.....	67
3.5 WP1.4: Price simulation .....	70
3.6 WP1.5: Market access strategy development .....	80
3.6.1 Strategies for developing the PICO .....	82
3.6.2 Strategies beyond PICO.....	83
3.6.3 Dossier submission.....	85
3.6.4 Internal price references .....	85
3.6.5 External price references .....	85
3.6.6 Implementation.....	86
3.7 WP1.6: National scientific consultation .....	86

---

3.8	WP1.7: Early Access programmes .....	88
3.9	WP1.8: Stakeholder management .....	89
3.10	WP1.9: Monitoring.....	90
3.11	WP1.10: Strategy update .....	90
<b>4</b>	<b>EU Strategy Development.....</b>	<b>93</b>
4.1	Objective and Overview .....	93
4.2	WP2.1: Verification of EU HTA obligation.....	95
4.3	WP2.2: Simulation of consolidated PICO .....	97
4.4	WP2.3: Gap Analysis .....	100
4.5	WP2.4: Consolidated price simulation .....	102
4.6	WP2.5: Consolidated HTA strategy .....	107
4.6.1	Strategies around Joint Scientific Consultation (JSC).....	107
4.6.2	Strategies around assessment scope and submission for joint clinical assessment (EU dossier production).....	108
4.6.3	Strategies around EU HTA assessment (JCA report).....	109
4.6.4	Alignment within the organisation .....	109
4.7	WP2.6: Scientific Consultation .....	109
4.7.1	General process .....	111
4.7.2	Formats.....	113
4.7.3	Consultation request.....	115
4.7.4	Potential alternative avenues for getting HTA scientific consultation .....	118
4.8	WP2.7: Stakeholder management .....	118
4.9	WP2.8: Monitoring.....	120
4.10	WP2.9: Strategy Update .....	120
<b>5</b>	<b>EU Dossier Production.....</b>	<b>123</b>
5.1	Objective and overview.....	123
5.2	WP3.1: Identifying anticipated PICOs .....	125
5.3	WP3.2: Statistical feasibility .....	126
5.4	WP3.3: EU dossier outline .....	128
5.5	WP3.4: EU dossier outline and national alignment.....	136
5.6	WP3.5: Statistical analysis .....	136
5.7	WP3.6: Dossier draft .....	137
5.8	WP3.7: Communication of final PICOs .....	139
5.9	WP3.8: Adaptation of dossier to final PICOs.....	142
5.10	WP3.9: Quality assurance .....	143
5.11	WP3.10: Dossier submission.....	144
5.12	WP3.11: Stakeholder management .....	145
5.13	WP3.12: Monitoring.....	146
<b>6</b>	<b>EU Assessment.....</b>	<b>147</b>
6.1	Objective and overview.....	147

---



---

6.2	JCA report – A general overview .....	148
6.2.1	General process .....	148
6.2.2	Timeline of the EU assessment phase .....	149
6.2.3	Incomplete dossier or no dossier submission .....	149
6.2.4	Contents of the JCA report .....	150
6.2.5	Updates of JCAs .....	151
6.3	WP5.1: Factual accuracy check .....	152
6.3.1	Factual accuracy check: Practical considerations .....	153
6.3.2	Commercially confidential information.....	155
6.4	WP5.2: Review of JCA report .....	155
6.5	WP5.3: Lessons learned.....	156
6.6	WP5.4: Stakeholder management.....	157
6.7	WP5.5: Monitoring .....	158
<b>7</b>	<b>National Dossier Production .....</b>	<b>159</b>
7.1	Objective and overview .....	159
7.2	WP4.1: Statistical feasibility.....	161
7.3	WP4.2: Dossier outline .....	162
7.4	WP4.3: Statistical analysis.....	164
7.5	WP4.4: Dossier preparation.....	165
7.6	WP4.5: Dossier alignment .....	166
7.7	WP4.6: Quality assurance.....	167
7.8	WP4.7: Dossier submission .....	168
7.9	WP4.8: Stakeholder management.....	169
7.10	WP4.9: Monitoring .....	170
<b>8</b>	<b>National Assessment .....</b>	<b>173</b>
8.1	Objective and overview .....	173
8.2	WP6.1: Assessment strategy.....	174
8.3	WP6.2: Dossier defense .....	176
8.4	WP6.3: Stakeholder management.....	177
8.5	WP6.4: Monitoring .....	178
8.6	WP6.5: Review the national HTA report.....	179
<b>9</b>	<b>National Price Negotiation .....</b>	<b>181</b>
9.1	Objective and overview .....	181
9.2	WP7.1: Negotiation strategy.....	183
9.3	WP7.2: Negotiation preparation .....	185
9.3.1	Evidence and price referencing .....	185
9.3.2	Scope of decision, and decision-making mechanism .....	186
9.3.3	Notification.....	186
9.4	WP7.3: Actual negotiation.....	186
9.5	WP7.4: Conflict resolution .....	187

---

---

9.6	WP7.5: Price submission.....	188
9.7	WP7.6: Stakeholder management .....	188
9.8	WP7.7: Monitoring.....	189
9.9	WP7.8: Lessons learned .....	190
9.10	WP7.9: Regional negotiation.....	191
<b>10</b>	<b>Getting started .....</b>	<b>193</b>
10.1	Monitoring.....	193
10.1.1	Constitutive framework.....	194
10.1.2	Relevant actors.....	194
10.1.3	Dynamics .....	197
10.2	Organisational set-up.....	199
10.2.1	Roles and responsibilities.....	199
10.2.2	Key processes.....	201
10.2.3	Adaptation of organisational structure .....	201
10.2.4	Resource requirements .....	202
10.3	HTA pipeline management.....	202
10.3.1	Verifying your HTA route: European or national HTA? .....	202
10.3.2	HTA planning per asset and indication: timeline, resources, responsibilities .....	204
10.3.3	Ad hoc approach and long-term preparation .....	207
10.4	Mock-up .....	208
10.4.1	National phase.....	209
10.4.2	European phase .....	210
10.5	Roadmap for internal preparation.....	212
	<b>List of abbreviations.....</b>	<b>215</b>
	<b>Key modifications in the update from October 2024.....</b>	<b>217</b>

---

## List of tables

Table 1:	Work packages, objectives, and deliverables in the EUnetHTA Project 2006–2008.....	10
Table 2:	Work packages, objectives, and deliverables in Joint Action 1 (2010–2012).....	13
Table 3:	Work packages, objectives, and deliverables in Joint Action 2 (2012–2015).....	15
Table 4:	Overview of the assessments carried out as part of JA2.....	17
Table 5:	Work packages, objectives, and deliverables in Joint Action 3 (2016–2021).....	19
Table 6:	Overview of relative effectiveness assessments performed for medicinal products during Joint Action 3 (JA3) .....	22
Table 7:	EUnetHTA 21 deliverables and guidance documents by the Coordination Group.....	43
Table 8:	Members of the EUnetHTA 21 consortium.....	49
Table 9:	Overview of mock PICO exercises performed by EUnetHTA 21 .....	51
Table 10:	Members of the Coordination Group.....	52
Table 11:	Overview of the members of the stakeholder network (as of June 2023).....	58
Table 12:	Conceptual distinction between pricing and reimbursement .....	71
Table 13:	Parameters of the generic dimensions of P&R .....	73
Table 14:	Institutions to monitor with regard to EU HTA activities .....	195



---

## List of figures

Figure 1:	National market access as the key challenge .....	1
Figure 2:	National market access encompassing both national HTA and national P&R.....	2
Figure 3:	Four phases of national market access .....	2
Figure 4:	EU HTA as a parallel work stream to national market access.....	3
Figure 5:	EU HTA and national market access are linked to each other .....	3
Figure 6:	Three phases of EU HTA work stream .....	3
Figure 7:	Market Access Core Model encompassing national market access and EU HTA work stream (overview) .....	4
Figure 8:	National strategy development informs EU strategy development .....	4
Figure 9:	EU dossier production flows from EU strategy development .....	5
Figure 10:	EU assessment flows from EU dossier production.....	5
Figure 11:	National dossier production flows from national strategy development, EU dossier production and EU assessment .....	5
Figure 12:	National assessment flows from EU assessment and national dossier production.....	6
Figure 13:	National price negotiation flows from national assessment and potentially the EU assessment .....	6
Figure 14:	National assessment flows from EU assessment and national dossier production.....	6
Figure 15:	Market Access Core Model® (Version 2.7).....	7
Figure 16:	From work stream to individual work package .....	8
Figure 17:	HTA Core Model® (dark blue: clinical domains; light blue: non-clinical domains).....	12
Figure 18:	Overview of steps towards the adoption of the EU HTA Regulation.....	24
Figure 19:	Overview of the four domains addressed by EU HTA and the five domains of the HTA Core Model® overseen by the individual member states .....	26
Figure 20:	Schematic overview of the structure of the HTAR.....	27
Figure 21:	Timeline when EU HTA will apply to different categories of medicinal products .....	28
Figure 22:	Schematic timetable for the adoption of Implementing Acts as of September 2024.....	32
Figure 23:	EMA timeline initial marketing authorization following a standard procedure.....	33
Figure 24:	EU HTA procedure according to HTAR .....	34

---

Figure 25:	EU HTA timeline initial marketing authorization following a standard EMA procedure.....	34
Figure 26:	EU HTA timeline initial marketing authorization following a standard EMA procedure (Gantt Chart) .....	35
Figure 27:	Process for developing assessment scope .....	36
Figure 28:	Parallelism of the EMA marketing authorisation procedure (in blue) and the European HTA process (in red). The number of days refers to the EMA timeline.....	39
Figure 29:	Differences between regulatory and HTA processes .....	40
Figure 30:	Guidelines published by the EUnetHTA 21 consortium .....	42
Figure 31:	Overview of the four subgroups of the Coordination Group .....	55
Figure 32:	Composition of the stakeholder network .....	57
Figure 33:	National strategy development is the first phase of the national market access work stream.....	61
Figure 34:	The ten work packages of national strategy development.....	62
Figure 35:	WP1.1 of national strategy development – Route of reimbursement.....	63
Figure 36:	Topology of national P&R and EU HTA scenarios .....	64
Figure 37:	WP1.2 of national strategy development – PICO simulation.....	65
Figure 38:	Typology of PICOs .....	65
Figure 39:	Components of PICO(S) .....	66
Figure 40:	WP1.3 of national strategy development – Gap analysis .....	68
Figure 41:	Generic final national HTA report .....	68
Figure 42:	From PICO to probable national HTA report .....	68
Figure 43:	From preferred national assessment to required evidence package .....	69
Figure 44:	Spotting the gaps.....	69
Figure 45:	WP1.4 of national strategy development – Price simulation .....	70
Figure 46:	Generic dimensions of P&R – Factors influencing the achievable price .....	72
Figure 47:	Exemplary overview of results of a price simulation.....	78
Figure 48:	Phases of strategic pricing in the product life cycle .....	79
Figure 49:	WP1.5 of national strategy development – Market access strategy .....	80
Figure 50:	Generic determinants of national market access work stream .....	80
Figure 51:	From P&R-determinants to a market access strategy .....	81
Figure 52:	National market access strategy by components and phases of national market access and EU HTA work streams.....	81
Figure 53:	WP1.6 of national strategy development – Scientific consultation.....	87
Figure 54:	Topology of consultation meeting formats .....	87
Figure 55:	WP1.7 of national strategy development – Early Access programmes.....	89

---

---

Figure 56:	WP1.8 of national strategy development – Stakeholder management.....	89
Figure 57:	WP1.9 of national strategy development – Monitoring.....	90
Figure 58:	WP1.10 of national strategy development – Strategy update.....	91
Figure 59:	EU strategy development as a second, parallel phase in the overall process.....	93
Figure 60:	Work packages of EU strategy development.....	94
Figure 61:	WP2.1 of EU strategy development – Verification of EU HTA obligation.....	95
Figure 62:	WP2.2 of EU strategy development – Simulation of consolidated PICO .....	97
Figure 63:	Process for simulating the consolidated PICOs.....	98
Figure 64:	Matrix linking national PICO input to assessment scope .....	99
Figure 65:	WP2.3 of EU strategy development – Gap analysis.....	100
Figure 66:	From PICO to probable JCA report.....	101
Figure 67:	From preferred EU assessment to required evidence package .....	101
Figure 68:	Spotting the gaps for EU HTA .....	102
Figure 69:	WP2.4 of EU strategy development – Consolidated price simulation.....	102
Figure 70:	Exemplary result matrix of national price simulations .....	104
Figure 71:	Overview of EUnetHTA 21 PICO exercise I on Pluvicto .....	105
Figure 72:	Exemplary result matrix of national price simulation with impact of EU HTA.....	106
Figure 73:	WP2.5 of EU strategy development – EU HTA Strategy.....	107
Figure 74:	WP2.6 of EU strategy development – Scientific consultation.....	110
Figure 75:	Topology of consultation meeting formats.....	111
Figure 76:	Timeline of EMA/HTAb Scientific Advice process.....	118
Figure 77:	WP2.7 of EU strategy development – Stakeholder management .....	119
Figure 78:	WP2.8 of EU strategy development – Monitoring .....	120
Figure 79:	WP2.9 of EU strategy development – Strategy update .....	120
Figure 80:	EU dossier production as a third phase in the overall process.....	123
Figure 81:	Work packages of EU dossier production .....	124
Figure 82:	WP3.1 of EU dossier production – Identification of anticipated PICOs .....	125
Figure 83:	WP3.2 of EU dossier production – Statistical feasibility .....	126
Figure 84:	Decision tree to assess the evidence available for each PICO.....	127
Figure 85:	WP3.3 of EU dossier production – EU dossier outline .....	128
Figure 86:	Submission dossier template structure .....	129
Figure 87:	Schematic representation of the content of Part 5 .....	130

---

---

Figure 88:	WP3.4 of EU dossier production – EU dossier outline and national alignment.....	136
Figure 89:	WP3.5 of EU dossier production – Statistical analysis .....	137
Figure 90:	WP3.6 of EU dossier production – Dossier draft.....	138
Figure 91:	WP3.7 of EU dossier production – Communication of final PICO .....	139
Figure 92:	Process for developing assessment scope .....	140
Figure 93:	WP3.8 of EU dossier production – Adaptation of dossier to final PICOs ....	142
Figure 94:	WP3.9 of EU dossier production – Quality assurance .....	143
Figure 95:	WP3.10 of EU dossier production – Dossier submission.....	144
Figure 96:	WP3.11 of EU dossier production – Stakeholder management .....	145
Figure 97:	WP3.12 of EU dossier production – Monitoring .....	146
Figure 98:	EU dossier assessment as fifth phase in the overall process .....	147
Figure 99:	Work packages of EU dossier assessment .....	147
Figure 100:	Procedural steps during the assessment phase of the JCA .....	149
Figure 101:	Content of the JCA report .....	151
Figure 102:	WP5.1 of EU assessment – Factual accuracy check .....	152
Figure 103:	Aspects of the JCA report that can be examined for errors or inaccuracies as part of the factual accuracy check .....	153
Figure 104:	WP5.2 of EU assessment – Review JCA report.....	156
Figure 105:	WP5.3 of EU assessment – Lessons learned.....	156
Figure 106:	WP5.4 of EU assessment – Stakeholder management.....	157
Figure 107:	WP5.5 of EU assessment – Monitoring .....	158
Figure 108:	National dossier production as a second phase of the national market access work stream.....	159
Figure 109:	National dossier production must align with national strategy development, EU dossier production, and EU assessment.....	160
Figure 110:	Work packages of national dossier production .....	160
Figure 111:	WP4.1 of national dossier production – Statistical feasibility .....	161
Figure 112:	JCA timelines for a standard regulatory process.....	162
Figure 113:	WP4.2 of national dossier production – Dossier outline.....	162
Figure 114:	WP4.3 of national dossier production – Statistical analysis.....	164
Figure 115:	WP4.4 of national dossier production – Dossier preparation.....	165
Figure 116:	WP4.5 of national dossier production – Dossier alignment.....	167
Figure 117:	WP4.6 of national dossier production – Quality assurance.....	167
Figure 118:	WP4.7 of national dossier production – Dossier submission .....	168
Figure 119:	WP4.8 of national dossier production – Stakeholder management.....	169

---



Figure 120: WP4.9 of national dossier production – Monitoring .....	170
Figure 121: Work packages of the National assessment phase.....	173
Figure 122: Key inputs driving the national assessment phase.....	173
Figure 123: National assessment phase and its five work packages .....	174
Figure 124: WP6.1 of national dossier assessment – Assessment strategy.....	174
Figure 125: National market access strategy by components and phases of market access work stream .....	175
Figure 126: WP6.2 of national dossier assessment – Dossier defense.....	176
Figure 127: WP6.3 of national dossier assessment – Stakeholder management.....	177
Figure 128: WP6.4 of national dossier assessment – Monitoring .....	178
Figure 129: WP6.5 of national assessment – Review the national HTA report.....	179
Figure 130: National price negotiation is the final phase in the national market access work stream .....	181
Figure 131: EU assessment and national dossier assessment inform the national price negotiation .....	182
Figure 132: Work packages of the national price negotiation phase .....	183
Figure 133: WP7.1 of national price negotiation – Negotiation strategy.....	183
Figure 134: National market access strategy by components and phases of the market access work stream.....	184
Figure 135: WP7.2 of national price negotiation – Negotiation preparation .....	185
Figure 136: WP7.3 of national price negotiation – Actual negotiation.....	187
Figure 137: WP7.4 of national price negotiation – Conflict resolution .....	188
Figure 138: WP7.5 of national price negotiation – Price notification.....	188
Figure 139: WP7.6 of national price negotiation – Stakeholder management.....	189
Figure 140: WP7.7 of national price negotiation – Monitoring.....	189
Figure 141: WP7.8 of national price negotiation – Lessons learned.....	190
Figure 142: WP7.9 of national price negotiation – Regional negotiation.....	191
Figure 143: Parallelism of the EMA marketing authorization procedure (in blue), the EU HTA process (in red), and the national HTA process (in grey). The size and length of the boxes do not necessarily correlate with actual time .....	200
Figure 144: Algorithm for determining the appropriate HTA route for a medicinal product.....	203
Figure 145: Applicability of the EU HTA obligation defines whether one or two work streams need to be addressed during the market access process .....	204
Figure 146: Depending on when the pivotal study is completed, an MAA can be timed to pursue national or EU HTA.....	205

---

Figure 147: Pathway through the relevant work packages of the Market Access Core Model for a mock-up assessment .....	209
Figure 148: Work packages for the national mock-up .....	210
Figure 149: Work packages for the EU mock-up .....	210
Figure 150: Example of roadmap for internal preparation .....	212

# 1 Market Access Core Model

**Dr. Thomas Ecker<sup>1</sup>**

From the outside, the proposed EU HTA might seem like a complex maze of rules and regulations: 36 articles packed into 32 pages just for the regulation itself, in addition to more than 60 high-quality deliverables from EUnetHTA 21 – not to mention the various Implementing Acts and corresponding guidelines, most of them still under development. All of these components are aimed at supporting national Health Technology Assessment (HTA) and Pricing & Reimbursement (P&R) as their main pillars of market access in 27 countries. It is easy to feel lost, even for those who consider the general concept of HTA to be common knowledge. So how can you see the forest for the trees?

This book does not aim to provide a detailed description of individual national market access systems within the context of EU HTA. Instead, it focuses on outlining general principles, enabling the reader to gain a comprehensive overview. To achieve this, adequate methodology is required. This should be generic enough to apply to most scenarios yet specific enough to offer practical guidance. This is where the Market Access Core Model comes into play.

Let's begin with the common denominator and the underlying basic idea: HTA in individual European countries predates EU HTA by several decades. As more and more countries adopted their own specific HTA procedures, the need for harmonisation and synergy at the European level became obvious. After all, the European Medicines Agency (EMA) covers 30 countries – Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden – and each has its own unique market access procedures. But if all of these procedures are different, what could possibly be the common denominator?

The answer lies in recognising that the individual market access procedures share a common link: the assessment of the clinical (and economic) evidence for medicinal products, specifically their HTA. It is through these interconnected assessments that the national market access procedure is formed, representing one of the key challenges when launching a new medicinal product (Figure 1).



Figure 1: National market access as the key challenge

For the scope of this book, the term “national market access” encompasses both the national Health Technology Assessment and the national Pricing & Reimbursement (P&R) processes (Figure 2).

<sup>1</sup> TE prepared the first edition of this chapter and updated this chapter in October 2024.




Figure 2: National market access encompassing both national HTA and national P&R

From the perspective of a pharmaceutical company, the national market access work stream can be delineated into four distinct phases (Figure 3).



Figure 3: Four phases of national market access

These four phases comprise the national work stream of the Market Access Core Model:

- **National strategy development:** This phase involves identifying the appropriate reimbursement process, simulating the likely outcome of the evidence evaluation and pricing decision, and developing the market access strategy based on these insights. Additionally, if applicable, the proposed approach is discussed with the pertinent authorities through a national scientific consultation, while also monitoring other (similar) procedures.
- **National dossier production:** In this phase, the strategy developed in the previous phase is executed by defining the outline of the evidence package (dossier), formulating the HTA Statistical Analysis Plan (SAP), and conducting the corresponding statistical analyses. It also encompasses the preparation of the actual dossier, quality check, dossier submission and product launch (if applicable).
- **National assessment:** Once the dossier is submitted, the national assessment phase begins. This involves developing the assessment strategy, interacting with authorities, and reviewing the final documents.
- **National price negotiation:** This phase encompasses developing the negotiation strategy, preparing the negotiation, conducting the actual negotiation process and resolution procedure, notifying the relevant authorities of the final price and reimbursement conditions, and, if needed, regional negotiation including tenders.

Lastly, stakeholder management and monitoring activities are crucial and should be addressed continuously throughout all phases of national market access.

So far, so good!

EU HTA is an additional work stream that runs parallel to national market access (Figure 4).